17 research outputs found
Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
BACKGROUND PIK3CA-related overgrowth spectrum (PROS) include a group of disorders that affect only the terminal portion of a limb, such as type I macrodactyly, and conditions like fibroadipose overgrowth (FAO), megalencephaly-capillary malformation (MCAP) syndrome, congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies (CLOVES) syndrome and Hemihyperplasia Multiple Lipomatosis (HHML). Heterozygous postzygotic PIK3CA mutations are frequently identified in these syndromes, while timing and tissue specificity of the mutational event are likely responsible for the extreme phenotypic variability observed.
METHODS:
We carried out a combination of Sanger sequencing and targeted deep sequencing of genes involved in the PI3K/AKT/mTOR pathway in three patients (1 MCAP and 2 FAO) to identify causative mutations, and performed immunoblot analyses to assay the phosphorylation status of AKT and P70S6K in affected dermal fibroblasts. In addition, we evaluated their ability to grow in the absence of serum and their response to the PI3K inhibitors wortmannin and LY294002 in vitro.
RESULTS AND CONCLUSION:
Our data indicate that patients' cells showed constitutive activation of the PI3K/Akt pathway. Of note, PI3K pharmacological blockade resulted in a significant reduction of the proliferation rate in culture, suggesting that inhibition of PI3K might prove beneficial in future therapies for PROS patients
AcrB Trimer Stability and Efflux Activity, Insight from Mutagenesis Studies
The multidrug transporter AcrB in Escherichia coli exists and functions as a homo-trimer. The assembly process of obligate membrane protein oligomers, including AcrB, remains poorly understood. In a previous study, we have shown that individual AcrB subunit is capable of folding independently, suggesting that trimerization of AcrB follows a three-stage pathway in which monomers first fold, and then assemble. Here we destabilized the AcrB trimer through mutating a single Pro (P223) in the protruding loop of AcrB, which drastically reduced the protein activity. We replaced P223 separately with five residues, including Ala, Val, Tyr, Asn, and Gly, and found that AcrBP223G was the least active. Detailed characterization of AcrBP223G revealed that the protein existed as a well-folded monomer after purification, but formed a trimer in vivo. The function of the mutant could be partly restored through strengthening the stability of the trimer using an inter-subunit disulfide bond. Our results also suggested that the protruding loop is well structured during AcrB assembly with P223 served as a âwedgeâ close to the tip to stabilize the AcrB trimer structure. When this wedge is disrupted, the stability of the trimer is reduced, accompanied by a decrease of drug efflux activity
Safety and efficacy of low-dose sirolimus in the PIK3CA-Related Overgrowth Spectrum
Purpose
PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth.
Methods
Thirty-nine participants with PROS and progressive overgrowth were enrolled into open-label studies across three centers, and results were pooled. For the primary outcome, tissue volumes at affected and unaffected sites were measured by dual energy X-ray absorptiometry during 26 weeks of untreated run-in and 26 weeks of sirolimus therapy.
Results
Thirty participants completed the study. Sirolimus led to a change in mean percentage total tissue volume of â7.2% (SD 16.0, pâ=â0.04) at affected sites, but not at unaffected sites (+1.7%, SD 11.5, pâ=â0.48) (nâ=â23 evaluable). Twenty-eight of 39 (72%) participants had â„1 adverse event related to sirolimus of which 37% were grade 3 or 4 in severity and 7/39 (18%) participants were withdrawn consequently.
Conclusion
This study suggests that low-dose sirolimus can modestly reduce overgrowth, but cautions that the side-effect profile is significant, mandating individualized riskâbenefit evaluations for sirolimus treatment in PROS
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results of an Italian multicenter study
Background Germline mutations in the STK11/LKB1 gene cause Peutz-Jeghers syndrome, an
autosomal-dominantly-inherited condition characterized by mucocutaneous pigmentation,
hamartomatous gastrointestinal polyposis, and an increased risk for various malignancies. We here
report the results of the first Italian collaborative study on Peutz-Jeghers syndrome.
Aims To assess cancer risks in a large homogenous cohort of patients with Peutz-Jeghers syndrome,
carrying, in large majority, an identified STK11/LKB1 mutation.
Methods One-hundred and nineteen patients with Peutz-Jeghers syndrome, ascertained in sixteen
different Italian centers, were enrolled in a retrospective cohort study. Relative and cumulative cancer
risks and genotype-phenotype correlations were evaluated.
Results 36 malignant tumors were found in 31/119 (29 STK11/LKB1 mutation carriers) patients, The
mean age at first cancer diagnosis was 41 years. The relative overall cancer risk was 15.1 with a
significantly higher risk (p<0.001) in females (22.0) than in males (8.6). Highly increased relative risks
were present for gastrointestinal (126.2) and gynecological cancers (27.7), in particular for pancreatic
(139.7) and cervical cancer (55.6). The Kaplan-Meier estimates for overall cumulative cancer risks
were 20%, 43%, 71%, and 89%, at age 40, 50, 60 and 65 years, respectively.
Conclusion Peutz-Jeghers syndrome entails markedly elevated cancer risks, mainly for pancreatic and
cervical cancers. This study provides a helpful reference for improving current surveillance protocols
Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740Gâ>âA mutation in PIK3CA gene
Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations
Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results of an Italian multicenter study
BACKGROUND: Germline mutations in the STK11/LKB1 gene cause Peutz-Jeghers syndrome, an autosomal-dominantly inherited condition characterized by mucocutaneous pigmentation, hamartomatous gastrointestinal polyposis, and an increased risk for various malignancies. We here report the results of the first Italian collaborative study on Peutz-Jeghers syndrome. AIMS: To assess cancer risks in a large homogenous cohort of patients with Peutz-Jeghers syndrome, carrying, in large majority, an identified STK11/LKB1 mutation. METHODS: One-hundred and nineteen patients with Peutz-Jeghers syndrome, ascertained in sixteen different Italian centres, were enrolled in a retrospective cohort study. Relative and cumulative cancer risks and genotype-phenotype correlations were evaluated. RESULTS: 36 malignant tumours were found in 31/119 (29 STK11/LKB1 mutation carriers) patients. The mean age at first cancer diagnosis was 41 years. The relative overall cancer risk was 15.1 with a significantly higher risk (p<0.001) in females (22.0) than in males (8.6). Highly increased relative risks were present for gastrointestinal (126.2) and gynaecological cancers (27.7), in particular for pancreatic (139.7) and cervical cancer (55.6). The Kaplan-Meier estimates for overall cumulative cancer risks were 20%, 43%, 71%, and 89%, at age 40, 50, 60 and 65 years, respectively. CONCLUSION: Peutz-Jeghers syndrome entails markedly elevated cancer risks, mainly for pancreatic and cervical cancers. This study provides a helpful reference for improving current surveillance protocols